A New Pillar of Medicine

Working in the emerging field of regenerative medicine, our scientists and clinicians are extraordinarily bold and optimistic about the impact their research may someday have on the lives of patients. We are operating at a unique moment in medical innovation, and we intend to maintain our leadership in the area of Regenerative Ophthalmology as we develop transformative new therapies to address some of the most significant unmet medical needs in eye diseases and vision loss. These include potential treatments for diseases affecting the retina, such as age-related macular degeneration (dry AMD) and Stargardt’s disease (SMD) – as well as other forms of macular degeneration, diabetic retinopathy and retinitis pigments, inflammatory diseases such as uveitis, and vision loss from photoreceptor and other neurosensory retinal damage due to glaucoma.

Copyright © 2005 - 2009 Astellas Pharma US, Inc.